The following review article was released on PubMed recently. It may explain the interest in INSM this week.
Ther Deliv. 2013 Aug;4(8):1047-72. doi: 10.4155/tde.13.71.
Liposomal formulations for inhalation.
I am doing fine with my investment in SHIRE; I will not be buying INSM. I do appreciate the posters on this board who did help me profit from my earlier interest in this stock. I will let you know, if there are any developments with ROP.
Thanks accu.Like to hear the ROP story.The interest this week in Insmed is what happens with the 68 M Insmed raised recently after the results from phase3 disappointed....positioning is led by the short king Lazard...for a min I was worried about my short - today I added....bios remain strong Good Luck